• Oncology Conference Insight: ESMO 2016 --- Faslodex® (fulvestrant, AstraZeneca) was approved in 2002 for the treatment of postmenopausal metastatic hormone receptor (HR)-positive breast cancer patients following prior anti-estrogen therapy. To date, utilization of Faslodex has favored second- and third-line settings for this indication, while aromatase inhibitors (AI) are generally favored in the first line for postmenopausal patients.
  • Although short-term financial results from such approach cannot be expected and many of the patient-centric efforts are gestural at this stage, the idea that we should invest our attention in patients in the long term suggests why we have to focus more on patients.
  • Heart disease is the leading cause of death worldwide. According to data from the World Health Organization (WHO), about 17.5 million people die every year due to heart diseases, approximately 31% of all deaths around the globe.
  • Market Access: An Industry Perspective

    by Indira Umareddy  |  Sep 29, 2016
    Almost every pharmaceutical company has a vertical assigned to market access function, and it is widely acknowledged as a critical part of brand planning and commercial success. But ask anyone what market access is and the chances are that you will get diverse answers.
  • On the Horizon of Cancer: The Future of Immunotherapy

    by Jay Grisolano  |  Sep 26, 2016
    We are in a unique time within cancer therapy, where significant resources are being used to develop drugs that target the immune system to fight cancer. Now we embark on a new endeavor in which most of the work is not discovering novel agents but developing a better understanding how to improve the use of therapies we have available.
More than one Google Analytics scripts are registered. Please verify your pages and templates.